Do I need to stop taking crizotinib first when replacing brigatinib?

When considering switching from crizotinib to brigatinib, the need to first discontinue the drug is an important issue involving patient treatment continuity and safety.

Crizotinib and brigatinib are both targeted therapies for ALK (anaplastic lymphoma kinase)-positive non-small cell lung cancer. They prevent the growth and spread of cancer cells by inhibiting the ALK signaling pathway.

Before changing medications, the patient's overall condition needs to be assessed, including the tumor's response to crizotinib, whether drug resistance has developed, and the patient's physical tolerance.

Based on clinical experience and professional guidelines, switching from crizotinib to brigatinib can usually be done directly without first discontinuing the drug. This is because the two drugs have similar mechanisms of action, and brigatinib may still be effective in some cases in patients who are resistant to crizotinib.

When changing dressings, adjustments should be made based on the patient’s specific conditions and the recommended dose of brigatinib. Generally speaking, the starting dose of brigatinib is 90mg once a day. After continuous administration for 7 days, if there are no obvious side effects, it can be increased to 180mg once a day.

During dressing change, the patient's condition changes, drug side effects, quality of life and other indicators should be closely monitored. Imaging studies and laboratory tests were performed periodically to assess brigatinib efficacy and patient tolerability.

Before changing medications, you should know whether the patient is taking other medications to avoid interactions with brigatinib. Before dressing change, patients should be fully educated to understand the mechanism of action, usage and dosage of brigatinib, possible adverse reactions and countermeasures. The entire dressing change process should be carried out under the guidance of a doctor to ensure patient safety and efficacy.